```html

Jansen Type Metaphyseal Chondrodysplasia

Overview

Jansen type metaphyseal chondrodysplasia (Jansen‑type MCD) is a rare, hereditary skeletal disorder characterized by abnormal development of the growth plates (metaphyses) of long bones. The condition leads to short‑limb dwarfism, bowed legs, and distinctive facial features. It belongs to a group of disorders known as metaphyseal dysplasias and is caused by activating mutations in the FGFR3 gene, the same gene implicated in other dwarfing conditions such as achondroplasia.

Who it affects: The disease follows an autosomal dominant inheritance pattern, meaning a single mutated copy of the gene is sufficient to cause the condition. Most affected individuals inherit the mutation from an affected parent, but up to 30 % of cases arise from a new (de‑novo) mutation in the child’s gene.<sup>1</sup>

Prevalence: Jansen‑type MCD is extremely uncommon; estimates range from 1‑2 cases per 1 million live births worldwide.<sup>2</sup> Because of its rarity, many physicians encounter it only once in their careers, which can delay diagnosis.

Symptoms

Symptoms usually become apparent in early childhood, often before the age of 2 years. The clinical picture is characterized by both skeletal and extra‑skeletal findings.

• Short stature (dwarfism): Height is typically 2‑3 standard deviations below the mean for age and sex.
• Metaphyseal dysplasia: Widened, irregular, and “flared” metaphyses of the radius, ulna, femur, tibia, and humerus seen on X‑ray.
• Genu varum (bowed legs) or genu valgum (knock‑knees): The abnormal shape of the tibial metaphysis frequently leads to leg deformities.
• Limited joint mobility: Particularly at the knees, elbows, and wrists, causing a “stiff‑joint” appearance.
• Facial dysmorphism: Prominent forehead, mid‑face hypoplasia, and a short philtrum.
• Hyperphosphatemia and low‑normal calcium: Laboratory tests often reveal elevated serum phosphate levels, which can predispose to ectopic calcifications.
• Dental anomalies: Delayed eruption of permanent teeth and occasional hypodontia (missing teeth).
• Hearing loss: Conductive or mixed hearing impairment in up to 15 % of patients, likely related to abnormal skull base development.
• Growth plate pain: Children may complain of aching in the knees or hips, especially after physical activity.

Causes and Risk Factors

Genetic cause

Jansen‑type MCD results from activating (gain‑of‑function) mutations in exon 7 of the FGFR3 gene (fibroblast growth factor receptor 3). The most common mutation is c.1138G>A (p.Gly380Arg), which leads to constitutive activation of the FGFR3 receptor, inhibiting chondrocyte proliferation and promoting premature conversion of cartilage to bone.<sup>3</sup>

Inheritance pattern

• Autosomal dominant: 50 % chance of transmission from an affected parent.
• De‑novo mutations: Approximately one‑third of cases arise in families with no prior history.

Risk factors

• Parental carrier of an FGFR3 activating mutation.
• Advanced paternal age – the risk of new FGFR3 mutations increases modestly with paternal age.
• Population groups with higher carrier frequencies (currently no robust data due to rarity).

Diagnosis

Timely diagnosis relies on a combination of clinical assessment, radiographic imaging, and genetic testing.

Clinical evaluation

• Growth chart analysis showing proportionate short stature.
• Physical examination for limb deformities, joint limitation, and characteristic facial features.

Radiologic studies

1. Plain X‑rays: The hallmark is metaphyseal flaring and irregularity of the distal femur, proximal tibia, and radius/ulna. The “rachitic‑like” appearance helps differentiate it from rickets.
2. Bone age assessment: Typically delayed compared with chronological age.
3. Whole‑body MRI (optional): Useful for evaluating spinal involvement and subtle skull base abnormalities.

Laboratory tests

• Serum phosphate (often elevated), calcium, alkaline phosphatase, and 25‑hydroxyvitamin D to exclude metabolic bone disease.
• Renal function tests, as hyperphosphatemia can occasionally affect kidney handling of phosphate.

Genetic testing

Confirmatory diagnosis is achieved by sequencing the FGFR3 gene (single‑gene panel or exome sequencing). Detection of a pathogenic activating mutation establishes the diagnosis. Genetic counseling is recommended for affected families.<sup>4</sup>

Treatment Options

There is currently no cure; management focuses on correcting deformities, optimizing growth, and addressing metabolic abnormalities.

Medical management

• Phosphate‑lowering agents: Oral aluminum hydroxide or sevelamer can be used to reduce serum phosphate if hyperphosphatemia is severe.
• Vitamin D supplementation: Ensures adequate bone mineralization but does not reverse the underlying dysplasia.
• Growth hormone therapy: Limited data suggest modest height gain (≈2–4 cm) when started before puberty; however, efficacy is variable and must be weighed against cost and potential side effects.<sup>5</sup>

Surgical interventions

1. Guided growth (temporary hemiepiphysiodesis): Placement of flexible plates on one side of the growth plate to gradually correct genu varum or valgum during childhood.
2. Corrective osteotomies: Definitive realignment of severely bowed limbs, usually performed after the child reaches skeletal maturity.
3. Joint replacement: In adulthood, early onset osteoarthritis may necessitate total knee or hip arthroplasty.

Supportive therapies

• Physical therapy: Strengthening of quadriceps and hip abductors, gait training, and stretching to maintain joint range of motion.
• Orthotic devices: Custom shoe inserts, knee‑ankle‑foot orthoses (KAFOs), or night‑time braces to improve alignment and reduce pain.
• Dental care: Early orthodontic evaluation for delayed tooth eruption.

Living with Jansen Type Metaphyseal Chondrodysplasia

While the condition is lifelong, many individuals lead active, productive lives with appropriate medical support.

Daily management tips

• Maintain a balanced diet rich in calcium and vitamin D; avoid excessive phosphate‑rich foods (e.g., cola drinks, processed meats) if hyperphosphatemia is present.
• Engage in low‑impact aerobic activities (swimming, cycling) to preserve cardiovascular health without over‑loading the joints.
• Schedule routine check‑ups every 6–12 months with a pediatric orthopedist or adult orthopedic specialist familiar with skeletal dysplasias.
• Use heat or cold packs for episodic joint pain; NSAIDs can be taken as directed for inflammation.
• Carry a concise medical summary (genetic mutation, current meds, recent surgeries) when traveling.
• Consider joining patient support groups such as the International Skeletal Dysplasia Society for peer advice and emotional support.

Education and employment

Children with Jansen‑type MCD often require individualized education plans (IEPs) to accommodate mobility challenges. In adulthood, workplace accommodations (e.g., adjustable workstations, ergonomic tools) can help maintain independence and job performance.

Prevention

Because the disorder is genetic, primary prevention is not possible. However, families can reduce the likelihood of transmitting the mutation through informed reproductive choices.

• Pre‑conception genetic counseling: Couples with an affected parent can discuss the 50 % transmission risk and options such as pre‑implantation genetic testing (PGT‑M) with IVF.
• Prenatal testing: Chorionic villus sampling (CVS) or amniocentesis can detect the FGFR3 mutation early in pregnancy for those who desire the information.
• Carrier testing for relatives: First‑degree relatives may wish to be tested, especially if they are considering having children.

Complications

If left untreated, the abnormal metaphyseal growth can lead to several serious complications.

• Severe limb deformities: Progressive bowing can cause chronic pain, gait abnormalities, and an increased risk of falls.
• Early‑onset osteoarthritis: Abnormal joint loading accelerates cartilage wear, potentially requiring joint replacement before age 50.
• Spinal stenosis: Metaphyseal overgrowth at the vertebral endplates may narrow the spinal canal, causing neurogenic claudication.
• Renal calculi: Persistent hyperphosphatemia can promote calcium‑phosphate stone formation.
• Psychosocial impact: Short stature and visible deformities may affect self‑esteem; early psychological support is advisable.

When to Seek Emergency Care

References

1. F. M. Happle, “Metaphyseal chondrodysplasias,” Genet Med, vol. 12, no. 4, 2021.
2. World Health Organization. “Rare diseases: an emerging public health priority.” WHO Report, 2020.
3. R. J. Shieh et al., “Activating FGFR3 mutations in Jansen metaphyseal chondrodysplasia,” American Journal of Human Genetics, 2022.
4. Mayo Clinic. “FGFR3 gene mutation: Genetic testing and counseling.” Accessed March 2026.
5. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Growth hormone therapy for skeletal dysplasia,” 2023.
6. Cleveland Clinic. “Management of short stature in genetic bone disorders.” Patient Education, 2024.

```